<DOC>
	<DOCNO>NCT00398437</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure , magnetic resonance imaging ( MRI ) , may help doctor find CNS metastasis plan treatment . PURPOSE : This randomized clinical trial study well MRI find CNS metastasis woman stage IV breast cancer .</brief_summary>
	<brief_title>Magnetic Resonance Imaging Early Detection CNS Metastases Women With Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine survival ( without neurological symptom due CNS metastasis ) woman HER2/neu-overexpressing stage IV breast cancer undergo gadolinium-enhanced magnetic resonance imaging ( MRI ) brain every 4 month vs every 12 month early detection CNS metastases . Secondary - Determine total number therapeutic procedure ( i.e. , gamma-knife , radiotherapy , surgery ) require treatment brain metastasis woman . - Determine total number hospitalization day require woman . - Determine overall survival woman . - Evaluate cross-platform , manufacturer-independent MRI technique diagnosis brain metastasis could use future study IRIS ULB-Canceropôle network . - Compare 2D-SE v 3D-GE thin section method post-contrast brain imaging woman . OUTLINE : This prospective , randomize study . Patients randomize 1 2 arm . - Arm I : Patients undergo gadolinium-enhanced magnetic resonance imaging ( MRI ) brain baseline ( exclude CNS involvement ) every 4 month ( early symptom possibly relate CNS involvement develop ) absence development CNS metastasis . - Arm II : Patients undergo gadolinium-enhanced MRI brain baseline ( exclude CNS involvement ) every 12 month ( early symptom possibly relate CNS involvement develop ) absence development CNS metastasis . Patients complete neurological symptom questionnaire baseline , every 6 week study intervention , completion study . PROJECTED ACCRUAL : A total 96 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer Stage IV disease HER2/neuoverexpression ( 3+ immunohistochemistry AND/OR gene amplification fluorescence situ hybridization ) Undergoing treatment trastuzumab ( Herceptin® ) ( alone together chemotherapy ) weekly 3 time weekly AND achieve respond stable disease ≥ 12 week No CNS metastasis ( i.e. , brain parenchymal lesion and/or leptomeningeal carcinomatosis ) No uncontrolled metastatic disease study entry Hormone receptor status Not specify PATIENT CHARACTERISTICS : Female Menopausal status specify Karnofsky performance status 70100 % No contraindication MRI scan PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>tumor metastatic brain</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>